Cancer is a key public health concern and a tremendous burden on European societies and economies. The number of new cases is expected to rise by about 70% over the next 2 decades and the need to combat the disease is highlighted in both national and European action strategies. Brachytherapy, one of the most common cancer treatment methods, represents the internal radiation therapy method, commonly used as an effective treatment for cervical, prostate, breast, skin cancer and tumors by placing radioactive sources directly into or next to the area requiring treatment. Miscalculation and mistakes in dose calculation algorithms cause inaccuracy in treatment plan, which results in a continuously flawed treatment. This can induce insufficient amount of radiation, over radiation, secondary cancer and radiation burns. In order to increase the effectiveness and quality of cancer treatment in brachytherapy procedures, BarchyDOSE, treatment quality control systems was developed. BarchyDOSE will enable technicians to adjust the treatment plan. The application of BrachyDOSE, effective quality control system will help to prevent secondary illnesses caused by primary treatment, which costs billions of euros for clinics and insurance institution each year. Overall objectives: to develop and elaborate feasibility study for BrachyDOSE commercialization that would include: a thorough analysis of HDR brachytherapy market and user needs, and a business plan with an extensive financial, pricing, and IPR strategy. These results would help to ensure that a fully operational model of BrachyDOSE is tailored for the target user needs and will guarantee its successful commercialization.
